Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRISBullishIndustry Newsnews

High materiality7/10

Curis updates boost PCNSL data and CLL enrollment, signaling regulatory optionality

Jul 22, 2026, 7:06 AM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong BTKi-naïve PCNSL data and faster enrollment in TakeAim CLL provide upside if sustained; regulatory tailwinds and webcast timing could trigger a sentiment-driven lift, though cash runway risk adds downside cap.

AI summary

What happened, with direct paths to the underlying reporting

Curis announced updated TakeAim PCNSL results and stronger TakeAim CLL enrollment, with year-end data guidance raised. BTKi-naïve PCNSL patients show 100% ORR; BTKi-experienced 33% ORR, signaling potential regulatory progress. While data quality supports a near-term regulatory pathway, the company’s cash runway remains a funding risk.

Curis to host webcast on TakeAim data and year-end CLL guidance.
PCNSL TakeAim data shows BTKi-naïve 100% ORR; BTKi-experienced 33% ORR.
TakeAim CLL enrollment progress; 10 consented; 5-10 data by Dec 2026.
Curis cites cash runway risk requiring substantial additional funding.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Curis updates boost PCNSL data and CLL enrollment, signaling regulatory optionality

Analyst raises CRIS PT to $43 on TakeAim CLL and timeline shifts